- Current report filing (8-K)
24 May 2012 - 7:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
May 23, 2012
Date of Report (Date of earliest event reported)
BIOLASE
TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-19627
|
|
87-0442441
|
(State of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
4 Cromwell
Irvine, California 92618
|
(Address of principal executive offices) (Zip Code)
|
(949) 361-1200
(Registrants telephone number, including area code)
Not
Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On May 23, 2012, Frederick Furry, Chief Operating Officer and Chief Financial Officer of Biolase Technology, Inc. (the Company) will deliver a presentation at the 13th Annual B.
Riley & Co. Investor Conference that will include a written communication comprised of slides. The slides from the presentation are attached hereto as Exhibit 99.1, and are hereby incorporated by reference
A copy of the slides will be available for viewing and download at http://www.biolase.com/investors for a period of 30 days.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Presentation material from the 13th Annual B. Riley & Co.
Investor Conference, dated May 23, 2012.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
BIOLASE TECHNOLOGY, INC.
|
|
|
|
Date: May 23, 2012
|
|
By:
|
|
/s/ Federico Pignatelli
|
|
|
|
|
Federico Pignatelli
|
|
|
|
|
Chairman and Chief Executive Officer
|
3
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Presentation material from the 13th Annual B. Riley & Co. Investor Conference, dated May 23, 2012.
|
4
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From May 2024 to Jun 2024
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Biolase Technology, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles